Feb 13, 2020 4:35pm EST DiaMedica Therapeutics Announces Closing of $8.5 Million Public Offering of Common Shares
Dec 17, 2019 4:14pm EST DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease
Nov 13, 2019 4:12pm EST DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update
Nov 06, 2019 4:04pm EST DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019
Nov 05, 2019 4:04pm EST DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference
Oct 14, 2019 7:42am EDT DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
Sep 06, 2019 9:00am EDT DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
Sep 03, 2019 4:15pm EDT DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
Aug 13, 2019 4:35pm EDT DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
